| Literature DB >> 31258774 |
Weipu Mao1, Ziwei Zhang1, Xin Huang1, Jie Fan2, Jiang Geng1.
Abstract
Purpose: We aimed to reveal the effects of marital status on survival outcomes in patients with penile cancer.Entities:
Keywords: SEER; cancer survival; marital status; penile cancer
Year: 2019 PMID: 31258774 PMCID: PMC6584924 DOI: 10.7150/jca.32037
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
Characteristics for penile cancer patients stratified by marital status.
| Characteristic | Total | Married | Divorced/Separated | Widowed | Single | P value |
|---|---|---|---|---|---|---|
| No. (%) | No. (%) | No. (%) | No. (%) | |||
| Total | 3195 | 1951 (61.1) | 365 (11.4) | 327 (10.2) | 552 (17.3) | |
| Age at diagnosis | <0.001 | |||||
| <60 | 938 (29.4) | 534 (27.4) | 106 (29.0) | 15 (4.6) | 283 (51.3) | |
| ≥60 | 2257 (70.6) | 1417 (72.6) | 259 (71.0) | 312 (95.4) | 269 (48.7) | |
| Race | <0.001 | |||||
| White | 2678 (83.8) | 1675 (85.9) | 311 (85.2) | 279 (85.3) | 413 (74.8) | |
| Black | 328 (10.3) | 144 (7.4) | 47 (12.9) | 34 (10.4) | 103 (18.7) | |
| Other | 189 (5.9) | 132 (6.8) | 7 (1.9) | 14 (4.3) | 36 (6.5) | |
| Urban-rural residence | 0.056 | |||||
| Metropolitan | 2654 (83.1) | 1626 (83.3) | 286 (78.4) | 280 (85.6) | 462 (83.7) | |
| Nonmetropolitan | 541 (16.9) | 325 (16.7) | 79 (21.6) | 47 (14.4) | 90 (16.3) | |
| Primary site | 0.014 | |||||
| Prepuce | 382 (12.0) | 253 (13.0) | 39 (10.7) | 38 (11.6) | 52 (9.4) | |
| Glans penis | 1070 (33.5) | 684 (35.1) | 107 (29.3) | 107 (32.7) | 172 (31.2) | |
| Body of penis | 175 (5.5) | 103 (5.3) | 29 (7.9) | 10 (3.1) | 33 (6.0) | |
| Overlapping lesion | 139 (4.4) | 85 (4.4) | 13 (3.6) | 13 (4.0) | 28 (5.1) | |
| Penis, NOS | 1429 (44.7) | 826 (42.3) | 177 (48.5) | 159 (48.6) | 267 (48.4) | |
| Histological Type | 0.071 | |||||
| Squamous cell carcinoma | 2879 (90.1) | 1738 (89.1) | 332 (91.0) | 299 (91.4) | 510 (92.4) | |
| Verrucous carcinoma | 173 (5.4) | 116 (5.9) | 17 (4.7) | 11 (3.4) | 29 (5.3) | |
| Others | 143 (4.5) | 97 (5.0) | 16 (4.4) | 17 (5.2) | 13 (2.4) | |
| SEER stage | 0.248 | |||||
| Localized | 1978 (61.9) | 1233 (63.2) | 218 (59.7) | 210 (64.2) | 317 (57.4) | |
| Regional | 1028 (32.2) | 606 (31.1) | 123 (33.7) | 102 (31.2) | 197 (35.7) | |
| Distant | 187 (5.9) | 111 (5.7) | 23 (6.3) | 15 (4.6) | 38 (6.9) | |
| Unstaged | 2 (0.1) | 1 (0.1) | 1 (0.3) | 0 (0.0) | 0 (0.0) | |
| Grade | 0.023 | |||||
| Grade I/Grade II | 2030 (63.5) | 1240 (63.6) | 212 (58.1) | 202 (61.8) | 376 (68.1) | |
| Grade III/Grade IV | 612 (19.2) | 359 (18.4) | 83 (22.7) | 65 (19.9) | 105 (19.0) | |
| Unknown | 553 (17.3) | 352 (18.0) | 70 (19.2) | 60 (18.3) | 71 (12.9) | |
| AJCC stage | 0.123 | |||||
| 0 | 25 (0.8) | 16 (0.8) | 2 (0.5) | 2 (0.6) | 5 (0.9) | |
| I | 1708 (53.5) | 1064 (54.5) | 194 (53.2) | 179 (54.7) | 271 (49.1) | |
| II | 661 (20.7) | 407 (20.9) | 65 (17.8) | 75 (22.9) | 114 (20.7) | |
| III | 519 (16.2) | 311 (15.9) | 69 (18.9) | 42 (12.8) | 97 (17.6) | |
| IV | 282 (8.8) | 153 (7.8) | 35 (9.6) | 29 (8.9) | 65 (11.8) | |
| T-stage | 0.031 | |||||
| Ta | 25 (0.8) | 16 (0.8) | 2 (0.5) | 2 (0.6) | 5 (0.9) | |
| T1 | 1869 (58.5) | 1162 (59.6) | 213 (58.4) | 190 (58.1) | 304 (55.1) | |
| T2 | 728 (22.8) | 451 (23.1) | 74 (20.3) | 80 (24.5) | 123 (22.3) | |
| T3 | 487 (15.2) | 281 (14.4) | 69 (18.9) | 42 (12.8) | 95 (17.2) | |
| T4 | 86 (2.7) | 41 (2.1) | 7 (1.9) | 13 (4.0) | 25 (4.5) | |
| N-stage | 0.034 | |||||
| N0 | 2620 (82.0) | 1619 (83.0) | 285 (78.1) | 278 (85.0) | 438 (79.3) | |
| N1 | 193 (6.0) | 104 (5.3) | 31 (8.5) | 22 (6.7) | 36 (6.5) | |
| N2 | 214 (6.7) | 129 (6.6) | 31 (8.5) | 10 (3.1) | 44 (8.0) | |
| N3 | 168 (5.3) | 99 (5.1) | 18 (4.9) | 17 (5.2) | 34 (6.2) | |
| M-stage | 0.093 | |||||
| M0 | 3097 (96.9) | 1902 (97.5) | 350 (95.9) | 317 (96.9) | 528 (95.7) | |
| M1 | 98 (3.1) | 49 (2.5) | 15 (4.1) | 10 (3.1) | 24 (4.3) | |
| Surgical therapy | 0.011 | |||||
| No | 200 (6.3) | 101 (5.2) | 33 (9.0) | 25 (7.6) | 41 (7.4) | |
| Yes | 1995 (93.7) | 1850 (94.8) | 332 (91.0) | 302 (92.4) | 511 (92.6) |
Abbreviations: SEER, Surveillance, Epidemiology and End Results; Grade I, Well differentiated; Grade II, Moderately differentiated; Grade III, Poorly differentiated; Grade IV, Undifferentiated; AJCC, American Joint Committee on Cancer; percentages may not total 100 because of rounding.
Kaplan-Meier analysis overall survival and cancer-specific survival for penile cancer patients.
| Characteristic | OS MST (months) | Kaplan-Meier | CSS MST (months) | Kaplan-Meier | ||
|---|---|---|---|---|---|---|
| Log Rank χ2 test | P value | Log Rank χ2 test | P value | |||
| Age at diagnosis | 114.547 | <0.001 | 18.655 | <0.001 | ||
| <60 | 38 | 42 | ||||
| ≥60 | 27 | 31 | ||||
| Marital status | 82.663 | <0.001 | 14.738 | 0.002 | ||
| Married | 33 | 38 | ||||
| Divorced/Separated | 28 | 34 | ||||
| Widowed | 22 | 23.5 | ||||
| Single | 26 | 29 | ||||
| Histological Type | 30.477 | <0.001 | 32.174 | <0.001 | ||
| Squamous cell carcinoma | 28 | 33 | ||||
| Verrucous carcinoma | 48 | 54 | ||||
| Others | 35 | 49 | ||||
| SEER stage | 347.495 | <0.001 | 468.526 | <0.001 | ||
| Localized | 38 | 44 | ||||
| Regional | 23 | 25 | ||||
| Distant | 8 | 9 | ||||
| Grade | 83.892 | <0.001 | 84.244 | <0.001 | ||
| Grade I/Grade II | 31 | 36 | ||||
| Grade III/Grade IV | 20 | 20 | ||||
| Unknown | 42 | 48 | ||||
| AJCC stage | ||||||
| 0 | 42 | 293.283 | <0.001 | 398.246 | <0.001 | |
| I | 39 | 48.5 | ||||
| II | 29 | 45 | ||||
| III | 22 | 31 | ||||
| IV | 9.5 | 24.5 | ||||
| T-stage | 111.027 | <0.001 | 158.953 | <0.001 | ||
| Ta | 42 | 48.5 | ||||
| T1 | 36 | 42 | ||||
| T2 | 26 | 28 | ||||
| T3 | 20 | 23 | ||||
| T4 | 13 | 17.5 | ||||
| N-stage | 261.080 | <0.001 | 438.318 | <0.001 | ||
| N0 | 35 | 41 | ||||
| N1 | 17 | 18 | ||||
| N2 | 14.5 | 14.5 | ||||
| N3 | 10 | 10.5 | ||||
| M-stage | 205.009 | <0.001 | 221.247 | <0.001 | ||
| M0 | 31 | 36 | ||||
| M1 | 7 | 8 | ||||
| Surgical therapy | 77.741 | <0.001 | 42.611 | <0.001 | ||
| No | 13 | 16 | ||||
| Yes | 31 | 36 | ||||
Abbreviations: MST, median survival time; OS, overall survival; CSS, cause-specific survival; SEER, Surveillance, Epidemiology and End Results; Grade I, Well differentiated; Grade II, Moderately differentiated; Grade III, Poorly differentiated; Grade IV, Undifferentiated; AJCC, American Joint Committee on Cancer
Risk factors for survival: outcome is overall survival and penis cancer-specific survival.
| Characteristic | OS | CSS | ||
|---|---|---|---|---|
| Hazard Ratio (95% CI) | P value | Hazard Ratio (95% CI) | P value | |
| Age at diagnosis | ||||
| <60 | Reference | Reference | ||
| ≥60 | 2.04 (1.77-2.36) | <0.001 | 1.69 (1.35-2.10) | <0.001 |
| Marital status | ||||
| Married | Reference | Reference | ||
| Divorced/Separated | 1.11 (0.93-1.32) | 0.238 | 0.95 (0.70-1.28) | 0.743 |
| Widowed | 1.73 (1.48-2.03) | <0.001 | 1.64 (1.19-2.25) | 0.002 |
| Single | 1.20 (1.02-1.40) | 0.026 | 1.24 (0.97-1.60) | 0.092 |
| Histological Type | ||||
| Squamous cell carcinoma | Reference | Reference | ||
| Verrucous carcinoma | 0.59 (0.43-0.81) | 0.001 | 0.26 (0.10-0.66) | 0.005 |
| Others | 1.10 (0.83-1.45) | 0.512 | 0.58 (0.27-1.28) | 0.179 |
| SEER stage | ||||
| Localized | Reference | Reference | ||
| Regional | 1.39 (1.21-1.60) | <0.001 | 1.20 (0.79-1.82) | 0.467 |
| Distant | 2.46 (1.66-3.64) | <0.001 | 1.98 (1.02-3.84) | 0.044 |
| Grade | ||||
| Grade I/Grade II | Reference | Reference | ||
| Grade III/Grade IV | 1.21 (1.06-1.39) | 0.005 | 1.32 (1.06-1.64) | 0.012 |
| Unknown | 0.84 (0.71-0.99) | 0.042 | 0.81 (0.58-1.13) | 0.210 |
| AJCC stage | ||||
| 0 | Reference | Reference | ||
| I | NA | 0.113 | 0.54 (0.07-4.26) | 0.555 |
| II | NA | 0.735 | 1.05 (0.13-8.50) | 0.967 |
| III | NA | 0.632 | 1.14 (0.14-9.47) | 0.907 |
| IV | NA | 0.227 | 1.30 (0.15-11.27) | 0.812 |
| T-stage | ||||
| Ta | Reference | Reference | ||
| T1 | NA | 0.095 | NA | 0.360 |
| T2 | NA | 0.796 | NA | 0.773 |
| T3 | NA | 0.294 | NA | 0.718 |
| T4 | NA | 0.027 | NA | 0.069 |
| N-stage | ||||
| N0 | Reference | Reference | ||
| N1 | 1.35 (1.08-1.69) | 0.008 | 2.10 (1.49-2.97) | <0.001 |
| N2 | 1.54 (1.24-1.92) | <0.001 | 2.23 (1.59-3.140 | <0.001 |
| N3 | 1.65 (1.21-2.24) | 0.001 | 2.17 (1.32-3.58) | 0.002 |
| M-stage | ||||
| M0 | Reference | Reference | ||
| M1 | 1.56 (1.07-2.29) | 0.021 | 1.94 (1.18-3.19) | 0.009 |
| Surgical therapy | ||||
| No | Reference | Reference | ||
| Yes | 0.56 (0.46-0.68) | <0.001 | 0.52 (0.38-0.72) | <0.001 |
Abbreviations: OS, overall survival; CSS, cause-specific survival; SEER, Surveillance, Epidemiology and End Results; Grade I, Well differentiated; Grade II, Moderately differentiated; Grade III, Poorly differentiated; Grade IV, Undifferentiated; AJCC, American Joint Committee on Cancer; NA, not applicable
Median survival months and survival months of penile cancer patients.
| Characteristic | OS MST (months) | Kaplan-Meier | CSS MST (months) | Kaplan-Meier | ||
|---|---|---|---|---|---|---|
| Log Rank χ2 test | P value | Log Rank χ2 test | P value | |||
| Localized | 95.335 | <0.001 | 12.127 | 0.007 | ||
| Married | 40.0 | 54.0 | ||||
| Divorced/Separated | 40.0 | 49.5 | ||||
| Widowed | 25.0 | 36.0 | ||||
| Single | 39.0 | 45.0 | ||||
| Regional | 11.060 | 0.011 | 5.024 | 0.170 | ||
| Married | 25.0 | 42.0 | ||||
| Divorced/Separated | 19.0 | 30.5 | ||||
| Widowed | 21.0 | 32.0 | ||||
| Single | 20.0 | 32.0 | ||||
| Distant | 4.864 | 0.182 | 2.212 | 0.530 | ||
| Married | 9.0 | 19.0 | ||||
| Divorced/Separated | 8.0 | 13.5 | ||||
| Widowed | 5.0 | 5.0 | ||||
| Single | 8.5 | 25.0 | ||||
| Grade I/Grade II | 54.129 | <0.001 | 12.052 | 0.007 | ||
| Married | 35.0 | 49.0 | ||||
| Divorced/Separated | 28.0 | 43.0 | ||||
| Widowed | 23.0 | 31.0 | ||||
| Single | 28.0 | 39.0 | ||||
| Grade III/Grade IV | 4.431 | 0.219 | 5.499 | 0.139 | ||
| Married | 20.0 | 32.0 | ||||
| Divorced/Separated | 19.0 | 37.0 | ||||
| Widowed | 20.0 | 31.0 | ||||
| Single | 15.0 | 33.0 | ||||
Abbreviations: OS, overall survival; CSS, cause-specific survival; Grade I, Well differentiated; Grade II, Moderately differentiated; Grade III, Poorly differentiated; Grade IV, Undifferentiated; NA, not applicable